Kezar Life Sciences, Inc.
$0
▼
-0.95%
2026-07-22 08:58:01
www.kezarlifesciences.com
NGM: KZR
Explore Kezar Life Sciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$53.86 M
Current Price
$0
52W High / Low
$7.55 / $3.53
Stock P/E
—
Book Value
$9.56
Dividend Yield
—
ROCE
-74.59%
ROE
-64.42%
Face Value
—
EPS
$-7.66
Exp Qtr EPS
—
Sector
Healthcare
KZR — Monthly Price History
Adjusted close price · Hover to see price & month
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Vertex Pharmaceuticals Incorporated | $451.63 | 26.79 | $114.63 B | — | — | 0.24% | $507.92 / $362.5 | $76.18 |
| 2. | Regeneron Pharmaceuticals, Inc. | $675.19 | 15.81 | $69.94 B | 0.56% | 10.23% | 14.32% | $821.11 / $541 | $295.71 |
| 3. | Revolution Medicines, Inc. | $183.29 | — | $38.94 B | — | -57.28% | -54.06% | $193.82 / $34 | $8.28 |
| 4. | Alnylam Pharmaceuticals, Inc. | $271.37 | 62.78 | $36.24 B | — | 14.33% | 98.29% | $495.55 / $266.27 | $5.96 |
| 5. | Roivant Sciences Ltd. | $34.96 | — | $33.71 B | — | -21.06% | -6.85% | $37 / $10.9 | $6.28 |
| 6. | Royalty Pharma plc | $58.42 | 40.45 | $33.47 B | 1.61% | 8.21% | 12.67% | $59.44 / $34.08 | $11.22 |
| 7. | Moderna, Inc. | $59.66 | — | $23.63 B | — | -29.7% | -36.73% | $85.6 / $22.28 | $21.95 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -8.33 M | -11.71 M | -14.6 M | -17.63 M | -21.57 M | — |
| Net Profit | -14.55 M | -11.23 M | -13.7 M | -16.56 M | -20.22 M | — |
| EPS in Rs | -1.97 | -1.52 | -1.86 | -2.25 | -2.74 | -2.78 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 7 M | 0 M |
| Operating Profit | -52.27 M | -89.14 M | -105.24 M | -71.16 M |
| Net Profit | -56.03 M | -83.74 M | -101.87 M | -68.24 M |
| EPS in Rs | -7.6 | -11.36 | -13.82 | -9.26 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 76.65 M | 144.68 M | 221.24 M | 299.57 M |
| Total Liabilities | 6.57 M | 27.77 M | 33.66 M | 29.7 M |
| Equity | 70.07 M | 116.92 M | 187.57 M | 269.87 M |
| Current Assets | 75.73 M | 137.49 M | 206.95 M | 285.72 M |
| Current Liabilities | 6.57 M | 20.33 M | 17.74 M | 11 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -51.78 M | -74.21 M | -81.64 M | -58.85 M |
| Investing CF | 92.46 M | 80.43 M | 76.05 M | -91.39 M |
| Financing CF | -10.59 M | 0.1 M | 0.64 M | 127.86 M |
| Free CF | -51.78 M | -74.24 M | -83.45 M | -60.42 M |
| Capex | -0.01 M | -0.03 M | -1.81 M | -1.58 M |
5Y Margin & Growth History
Last 5 years of annual financial statement data.
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | 33.08% | 17.8% | -49.28% | — |
| Profit Margin % | — | — | -1455.29% | — |
| Operating Margin % | — | — | -1503.39% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -1417.91% | — |
Dividend & Split History
Latest dividend payments and stock split events.
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-10-30 | 1:0.1 |